Abstract
Uterine sarcomas (US) are rare tumors representing less than 5 % of uterine malignancies. They carry a poor prognosis characterized by a high rate of local and metastatic recurrences. Surgical treatment consists in hysterectomy and bilateral oophorectomy; pelvic lymphnode dissection is recommended in carcinosarcomas only. Despite the high risks of metastatic evolution, few prospective randomised studies have been conduct in an adjuvant setting. Pelvic radiotherapy after surgery is recommended to enhance local control. The only phase III of adjuvant chemotherapy is negative but difficult to interpret. A French study is actually ongoing studying the effects of adjuvant polychemotherapy (adriamycin, cisplatin and ifosfamide).
| Translated title of the contribution | Uterine sarcomas |
|---|---|
| Original language | French |
| Pages (from-to) | 137-143 |
| Number of pages | 7 |
| Journal | Oncologie |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Mar 2007 |